New lab models for mature B-cell blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study creates lab models from blood samples of people with specific mature B-cell blood cancers (CLL, SMZL, HCL) to test new immune and combination treatments. This research may help find more personalized therapies for these diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You must have a diagnosis of chronic lymphocytic leukemia (CLL), splenic marginal zone lymphoma (SMZL), or hairy cell leukemia (HCL)
- You must be willing and able to give your own informed consent to take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tiny particles called extracellular vesicles in the blood of people with Hairy Cell Leukemia. Researchers want to understand if these particles can help improve how the disease is managed and followed.
This study collects human samples (like blood or other specimens) to learn more about hairy cell leukemia and other leukemias. It also helps researchers develop new lab-made immune-based medicines for cancer treatment.
This study looks at how cells talk to each other in hairy cell leukemia, a rare blood cancer. It aims to find ways to improve patient care. Participants may be asked to give blood or tissue samples for research.
This study looks at blood tests and genetic markers in people newly diagnosed with chronic lymphocytic leukemia (CLL). It aims to better understand the disease and may help guide future care.
This study watches the course of hairy cell leukemia (HCL) in different phases—when first diagnosed, after it comes back, or long after successful treatment. The goal is to better understand the disease and plan future care.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
Hear when a new Splenic Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.